Administration of blinatumomab to one pediatric patient

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2016-002372-27-HU

Enrollment

Registered

2016-05-31

Start date

2016-06-02

Completion date

Unknown

Last updated

2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-precursor acute lymphoblastic leukaemia MedDRA version: 19.0 Level: PT Classification code 10003890 Term: B precursor type acute leukaemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

Interventions

Trade Name: Blincyto Product Name: BLINCYTO 38.5 micrograms powder for concentrate and solution for solution for infusion Pharmaceutical Form: Concentrate and solvent for solution for infusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? yes Number of subjects for this age range: 1 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: Assessment of efficacy;Secondary Objective: assessment of safety;Primary end point(s): decrease in tumor mass, or disappearence of tumor	—

Countries

Hungary

Contacts

Public Contactprincipal investigator

BAZ Megyei és Egyetemi Oktató Kórház

reka.simondr@gmail.com0036703113961

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026